Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
January 24, 2022 08:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors
December 16, 2021 16:05 ET
|
Lyell Immunopharma, Inc
Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023ROR1-targeted CAR T-cell therapy designed to overcome...
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs
December 15, 2021 16:05 ET
|
Lyell Immunopharma, Inc
Lyell’s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programsLyFE Manufacturing Center integrates...
Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair
December 02, 2021 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights
November 12, 2021 08:00 ET
|
Lyell Immunopharma, Inc
Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell...
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
September 08, 2021 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
August 12, 2021 16:05 ET
|
Lyell Immunopharma, Inc
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trialsCash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021...
Lyell Immunopharma Announces Pricing of Initial Public Offering
June 16, 2021 21:49 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...